On 4 June 2013, Orion Corporation announced that it had resolved to issue a EUR 150 million fixed rate unsecured bond with a maturity of six (6) years.
The Finnish Financial Supervisory Authority has approved the listing prospectus of the bond today. The prospectus is available on Orion Corporation's website http://www.orion.fi/en/investors.
The Company has submitted an application to NASDAQ OMX Helsinki Ltd to apply for the listing of the bond. The bond is expected to be admitted to public trading on or about 12 June 2013.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.
Disclaimer
The information contained in this release shall not constitute an offer to sell securities of Orion Corporation in any jurisdiction. In particular, this release does not constitute an offer to sell securities in the United States. Any securities referred to herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended, and may not be offered, exercised or sold in the United States absent registration or an applicable exemption from registration requirements.